| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | S12; 5-HT1B; HTR1D2; HTR1DB; 5-HT1DB |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human HTR1B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于HTR1B抗体的虚构参考文献示例(仅供格式参考，内容非真实文献)：
---
1. **文献名称**: "Characterization of a Novel HTR1B Antibody for Neurotransmitter Receptor Localization Studies"
**作者**: Smith A, et al.
**摘要**: 该研究开发并验证了一种高特异性HTR1B抗体，用于检测小鼠和人类脑组织中的5-HT1B受体分布。抗体通过免疫组化和Western blot确认选择性，揭示了HTR1B在前额叶皮层和基底神经节的表达模式，为神经精神疾病研究提供工具。
2. **文献名称**: "HTR1B Receptor Antibody-Based Screening in Antidepressant Drug Development"
**作者**: Jones B, et al.
**摘要**: 利用HTR1B抗体进行高通量药物筛选，发现新型配体可调节受体活性。研究通过竞争性结合实验和细胞信号分析，证实抗体在鉴定靶向HTR1B的抗抑郁候选药物中的有效性。
3. **文献名称**: "HTR1B Antibody Reveals Altered Receptor Expression in Parkinson’s Disease Models"
**作者**: Chen L, et al.
**摘要**: 通过免疫荧光和流式细胞术，发现帕金森病模型中HTR1B表达水平显著下调，提示其与多巴胺能神经元功能异常相关。抗体特异性经KO小鼠模型验证，支持其在神经退行性疾病机制研究中的应用。
4. **文献名称**: "Cross-Reactivity Evaluation of Commercial HTR1B Antibodies: Implications for Serotonin Research"
**作者**: García R, et al.
**摘要**: 系统评估了市售HTR1B抗体的交叉反应性，发现部分抗体与HTR1A/HTR1D存在非特异性结合。研究提出标准化验证方案，强调抗体选择对5-HT受体精准研究的必要性。
---
注：以上文献为示例性质，实际引用时需查阅真实数据库(如PubMed)并核实原文。
The 5-hydroxytryptamine receptor 1B (HTR1B), a G protein-coupled receptor, plays a critical role in regulating neurotransmitter release, particularly serotonin, and is implicated in mood, anxiety, and depression. HTR1B antibodies are essential tools for studying this receptor’s expression, localization, and function in neurological and psychiatric research. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunocytochemistry (ICC) to detect HTR1B in tissues or cell lines, aiding in understanding its distribution in the central nervous system (e.g., basal ganglia, cortex) and peripheral tissues.
Research using HTR1B antibodies has linked receptor dysfunction to disorders such as depression, obsessive-compulsive disorder, and migraine, as well as responses to antidepressants and triptan medications. Antibodies targeting specific epitopes (e.g., extracellular or intracellular domains) help elucidate HTR1B's signaling pathways and interactions with ligands or drugs.
Validation of HTR1B antibodies includes testing in knockout models or siRNA-treated samples to confirm specificity. Cross-reactivity with related receptors (e.g., HTR1A) must be ruled out. Commercial antibodies vary in host species (rabbit, mouse) and applications, requiring careful selection based on experimental needs. Ongoing studies using these antibodies contribute to drug development and personalized therapies targeting serotonin-related disorders.
×
